Abstract
Background Human immunodeficiency virus (HIV) is associated with increased risk of heart failure (HF) but data regarding phenotypes of heart failure and outcomes after HF diagnosis, especially within the safety-net which is where half of people with HIV in the United States receive care, are less clear.
Methods Using an electronic health record cohort of all individuals with HF within a municipal safety-net system from 2001-2019 linked to the National Death Index Plus, we compared HF phenotypes, all-cause mortality, HF hospitalization, and cause of death for individuals with and without HIV.
Results Among people with HF (n=14,829), 697 individuals had HIV (4.7%). Persons with HIV (PWH) were diagnosed with HF ten years younger on average. A higher proportion of PWH had a reduced ejection fraction at diagnosis (37.9% vs 32.7%). Adjusted for age, sex, and risk factors, coronary artery disease on angiography was similar by HIV status. HIV was associated with 55% higher risk of all-cause mortality (HR 1.55; 95% CI 1.37-1.76; P<0.001) and lower odds of HF hospitalization (OR 0.51; 95% CI 0.39-0.66; P<0.001). Among PWH with HF, cause of death was less often attributed to cardiovascular disease (22.5% vs 54.6% uninfected; P<0.001) and more to substance use (17.9% vs 9.3%; P<0.001), consistent with autopsy findings in a subset (n=81).
Conclusions Among people with HF who receive care within a municipal safety-net system, HIV infection is associated with higher mortality, despite lower odds of HF hospitalization, attributable to non-cardiovascular causes including substance-related and HIV-related mortality.
Clinical Perspectives
People with HIV develop heart failure 10 years earlier than people without HIV, with a higher proportion with HFrEF at diagnosis.
HIV is associated with higher mortality among people with heart failure, primarily due to non-cardiovascular causes including HIV/AIDS and substance use.
Research Perspectives
The reasons for higher mortality in PWH with HF are not yet fully understood; higher levels of myocardial fibrosis may predispose people with substance use and advanced HIV disease to increased risk of mortality.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Not applicable/retrospective observational study.
Funding Statement
Dr. Durstenfeld is funded by NIH grant NIH/NLBI (K12 HL143961). This work was assisted in part by a CFAR-ARI Boost Award from the UCSF AIDS Research Institute and was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1TR001872. Dr. Tseng is funded by R01 HL157247 and the autopsy data were funded by R01HL102090. Dr. Hsue is funded by K24AI112393. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of California San Francisco Institutional Review Board approved this study and granted a waiver of consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Tweet: HIV associated with 55% higher mortality after #HeartFailure diagnosis in the safety-net, mainly from non-CVD causes inc. substance-related @durstenfeld @UCSFCardiology @UCSF_HIVIDGM @SF_POSTSCD
Disclosures: None of the authors have pertinent disclosures or relevant conflicts of interest.
Funding: Dr. Durstenfeld is funded by NIH grant NIH/NLBI (K12 HL143961). This work was assisted in part by a CFAR-ARI Boost Award from the UCSF AIDS Research Institute and was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1TR001872. Dr. Tseng is funded by R01 HL157247 and the autopsy data were funded by R01HL102090. Dr. Hsue is funded by K24AI112393. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
Data Availability
Deidentified data is available upon reasonable request to the corresponding author for non-commercial, scientific purposes.
Abbreviations
- HF
- Heart Failure
- HFrEF
- Heart Failure with Reduced Ejection Fraction
- HIV
- Human Immunodeficiency Virus
- PWH
- persons with HIV
